Top Performing Stocks To Buy For 2022

When you think about it, just about every investor is following a trend in one way or another. Whether they make money doing it, of course, is another question altogether.

Regardless of your time horizon — minutes or months — a financial instrument must move in your favor to be profitable. It is that simple. So finding a reliable indicator to measure trend could be critical to your success.

As it turns out, there is a simple, quantitative indicator we can use to find stocks with the propensity for a big move…

It’s called relative strength (RS).

What Is Relative Strength (RS)?

Relative strength investing is pretty straightforward. It involves buying the best-performing stocks relative to all other stocks. We then hold these stocks until their momentum changes course.

To most investors, especially “value-minded” investors, this strategy probably feels counterintuitive. After all, one of the first things you learn as an investor is to “buy low, sell high.” But what we feel and what we can prove are two very different things. And there are decades of research to prove the predictive power of this indicator.

Top Performing Stocks To Buy For 2022: Blue Capital Reinsurance Holdings Ltd.(BCRH)

Blue Capital Reinsurance Holdings Ltd., incorporated on June 24, 2013, is an exempted limited liability company. Through its subsidiaries, the Company provides collateralized reinsurance in the property catastrophe market and invests in various insurance-linked securities. The Company’s wholly owned subsidiaries include Blue Capital Re, which is a Bermuda exempted limited liability company registered as a Class 3A insurer in Bermuda and provides collateralized reinsurance and Blue Capital Re ILS, which is a Bermuda exempted limited liability company that conducts hedging and other investment activities, including entering into industry loss warranties and purchasing catastrophe bonds operations.

As of December 31, 2014, the Company had $201.3 million of consolidated total assets. Blue Capital Re provides reinsurance to third-party insurance and reinsurance companies through reinsurance contracts, either directly with the cedant or on a fronted basis. Blue Capital Re also provides facultative retrocessional reinsurance to Blue Water Re.

The Company competes with Aeolus Capital Management; CatCo; Credit Suisse Asset Management; Leadenhall Capital; Lloyd’s of London; Nephila Capital Ltd.; Pillar Capital; RenaissanceRe Holdings Ltd. and Validus Holdings, Ltd.

Advisors’ Opinion:

  • [By Stephan Byrd]

    RLI (NYSE: BCRH) and Blue Capital Reinsurance (NYSE:BCRH) are both finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

  • [By Max Byerly]

    News articles about Blue Capital Reinsurance (NYSE:BCRH) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Blue Capital Reinsurance earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news headlines about the insurance provider an impact score of 47.9769004082468 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

  • [By Shane Hupp]

    Blue Capital Reinsurance (NYSE:BCRH) reached a new 52-week high and low during trading on Thursday . The company traded as low as $10.90 and last traded at $11.05, with a volume of 17133 shares trading hands. The stock had previously closed at $11.20.

Top Performing Stocks To Buy For 2022: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said,Alnylam Pharmaceuticals (NASDAQ:ALNY)andPfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

Top Performing Stocks To Buy For 2022: TravelCenters of America LLC(TA)

TravelCenters of America LLC operates and franchises travel centers primarily along the United States interstate highway system. The company offers diesel fuel and gasoline, and diesel exhaust fluid; and operates full service restaurants under the Iron Skillet and Country Pride brands, as well as quick service restaurants primarily under Arby’s, Burger King, Dunkin’ Donuts, Godfather’s Pizza, Pizza Hut, Popeye’s Chicken & Biscuits, Starbuck’s Coffee, Subway, and Taco Bell brand names. It also operates truck repair and maintenance facilities that offer maintenance and emergency repair, and road services, such as oil changes, wheel alignments, and tire repair; and specialty services, including diagnostics and repair of air conditioning, brakes, and electrical systems. In addition, the company provides RoadSquad, a roadside truck service program; RoadSquad Connect, a centralized call center; and RoadSquad OnSite, a service program, as well as operates travel stores that offer packaged food and snack items, beverages, non-prescription drug and beauty supplies, batteries, automobile accessories, and music and video products. Further, it offers additional driver services, including specialized business services, which include information center; Reserve-It parking program; a banking desk; Wi-Fi Internet access; video game room; a laundry area; private showers; exercise facilities; and a theater or big screen television room. The company serves long haul trucking fleets and their drivers, independent truck drivers, and motorists. As of August 4, 2015, it operated 256 convenient full-service locations under the TravelCenters of America and Petro Stopping Centers brands in 43 states of the United States and Canada. The company also operated gasoline/convenience stores primarily under the Minit Mart brand. TravelCenters of America LLC was founded in 1992 and is headquartered in Westlake, Ohio.

Advisors’ Opinion:

  • [By Max Byerly]

    BidaskClub lowered shares of SmartFinancial (NASDAQ:SMBK) from a hold rating to a sell rating in a research note published on Thursday morning.

    A number of other analysts have also weighed in on SMBK. Zacks Investment Research upgraded SmartFinancial from a sell rating to a buy rating and set a $21.00 target price on the stock in a research note on Wednesday, January 16th. FIG Partners began coverage on SmartFinancial in a report on Friday, February 22nd. They issued an outperform rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $24.60.

  • [By Stephan Byrd]

    Media coverage about SmartFinancial (NASDAQ:SMBK) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SmartFinancial earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news stories about the bank an impact score of 45.289677526379 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Leave a Reply

Your email address will not be published.